Eli Lilly and Company has plans to build a $6bn active pharmaceutical ingredient (API) manufacturing facility in Huntsville, Alabama, an addition to the company’s expanding US production footprint.
"[This] is the largest initial investment in our state's history,” said Kay Ivey, Governor of Alabama.
The Alabama facility will be designed to expand the domestic production of synthetic and peptide APIs.
This includes the manufacture of orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which is primarily used for weight loss by mimicking the natural hormone to control blood sugar, reduce appetite and slow digestion.
Focus on GLP-1 for weight loss
Although the facility will support a broad portfolio of APIs, it is slated to manufacture orforglipron, Lilly’s first oral small-molecule GLP-1 receptor agonist, an emerging class of therapies targeting obesity and metabolic disorders.
GLP-1 helps with weight loss by mimicking the natural hormone to control blood sugar, reduce appetite and slow digestion.
The company plans to submit orforglibpron to global regulatory agencies for obesity by the end of this year.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.
Subscribe now Already a subscriber? Sign in here.